Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB0011 and CB0012 randomized dose-ranging study in obstructive sleep apnea syndrome
ACTRN12605000689673Phase 2Not yet recruiting
- Sponsor
- Cypress Bioscience, Inc.
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of mirtazapine and paroxetine in obstructive sleep apnea hypopnea syndrome (OSAHS) (5 arms), sponsored by Cypress Bioscience, Inc. Primary endpoints: Change in apnea-hypopnea index, Change in respiratory disturbance index and 1 more. Planned start Sep 2006; status: not yet recruiting.
02
Drugs
mirtazapineparoxetine
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12605000689673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000689673.